NCT02630693 2026-04-13
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
64 trialsNCT05659563 2026-03-19
EMPRESS
MedSIR
Phase 2 Completed
NCT00003042 2026-02-20
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT05101564 2026-02-12
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Stanford University
Phase 2 Completed
NCT00066690 2026-02-06
SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT00066703 2026-02-06
TEXT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT02668666 2026-01-20
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02101788 2025-11-13
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT00601900 2025-05-23
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT03346200 2025-03-07
KARISMA2
Karolinska Institutet
Phase 2 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT04079517 2025-02-06
Karisma-1
Karolinska Institutet
Phase 1/2 Completed
NCT02993159 2024-12-18
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Northwestern University
Phase 2 Completed
NCT02913430 2024-09-23
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT00072462 2024-09-19
IBIS-II DCIS
Queen Mary University of London
Phase 3 Completed
NCT02228681 2024-09-19
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT04129216 2024-05-07
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
Phase 2 Completed
NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT00499083 2023-09-29
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Phase 2 Completed
NCT01124695 2023-06-29
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02384239 2022-03-16
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
University of California, San Francisco
Phase 2 Completed
NCT01831076 2022-03-03
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
University of Colorado, Denver
Phase 2 Completed
NCT00710970 2022-01-24
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
Baylor College of Medicine
Phase 2 Completed
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02988986 2021-09-22
ANETT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02197897 2021-01-13
BCTamoxifen
Baylor College of Medicine
Phase 2 Completed
NCT00290745 2020-12-04
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
University of California, San Francisco
Phase 1/2 Completed
NCT01393990 2020-03-24
A Study of LY2228820 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00068419 2020-02-19
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
Children's Oncology Group
Phase 2 Completed
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00240071 2019-10-30
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
University of Alabama at Birmingham
Phase 2 Completed
NCT02093351 2019-10-02
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Phase 1 Completed
NCT00041080 2019-07-30
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00729586 2019-07-23
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00053898 2018-09-20
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
NSABP Foundation Inc
Phase 3 Completed
NCT00687102 2018-09-12
Co-STAR
Wake Forest University Health Sciences
Phase 3 Completed
NCT01614210 2018-08-01
POWER PIINC
University of Utah
Phase 2 Completed
NCT00728949 2018-06-06
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00194779 2018-03-12
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
University of Washington
Phase 2 Completed
NCT01027416 2017-12-13
Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
Roswell Park Cancer Institute
Phase NA Completed
NCT00118157 2017-12-04
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
National Cancer Institute (NCI)
Phase 2 Completed
NCT00764322 2017-08-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00003199 2017-07-12
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00171704 2017-03-03
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Novartis
Phase 3 Completed
NCT02806544 2017-01-30
Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
Vanderbilt University
Phase 2 Completed
NCT00293540 2016-07-27
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
International Breast Cancer Research Foundation
Phase 3 Completed